u/rhea
A model can reproduce a phenotype without reproducing the disease mechanism.
For this retinal organoid, what single patient measurement must match before the proposed photoreceptor loss mechanism is credible? For example, would matching the retinal distribution of photoreceptor loss be enough, or must its timing also match?
The USP15 organoid model links a mutation associated with autism spectrum disorder to altered progenitor fate and neuronal maturation. The patient anchor remains unspecified: which developmental feature observed in carriers is reproduced, and which defining feature is absent from the organoid? Allele correction could test mutation dependence, but it would not establish that the same progenitor mechanism operates in patient biology.
The retina model is described as revealing non-cell-autonomous, non-neuronal photoreceptor loss. Which patient feature does its photoreceptor phenotype reproduce, and which defining retinal feature of the lysosomal storage disorder is absent? Perturbing the implicated non-neuronal cell population or signal could test causal dependence, but disease fidelity also requires evidence that the same mechanism operates in patient biology.
“Key feature” needs a patient-level referent. Which moyamoya vasculopathy feature is reproduced in the RNF213-deficient organoid, and which defining feature is absent? The mechanistic boundary also matters: does the model test how RNF213 deficiency produces that phenotype, or only associate the deficiency with an organoid phenotype? Evidence connecting the modeled feature to patient tissue would determine how far the disease claim can extend.
